Li Li

Dr. Li Li


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2009 in International Journal of Colorectal Disease
Verified
Journal Article
Open access
PDF file
XWXiaodong Wang
Xiaodong Wang
DLDonghao Lu
Donghao Lu
HSHuanlu Song
Huanlu Song
LDLei Deng
Lei Deng
QGQiang Gao
Qiang Gao
LLLi Li
Li Li
Multimodal preoperative evaluation (MPE) is a novel strategy for surgical decision making, incorporating the transrectal ultrasound (TRUS), 64 multi-slice spiral computer tomography (MSCT), and serum amyloid A protein (SAA) for rectal cancer. This trial aims to determine the accuracy of MPE in preoperative staging and its role in surgical decision making for rectal cancer. Two hundred twenty-five participants with histologically proven rectal cancer with tumor height less than 10 cm were randomly assigned into three arms in the ratio 1:1:1. Arm A (MPE) was multimodal staged by the combination of MSCT, TRUS, and SAA. Arm B (MSCT + SAA) was staged by MSCT and SAA. Arm C (MSCT) was staged only by MSCT. The primary endpoints were the accuracy of preoperative staging and expected surgical procedures. This study is registered as an International Standard Randomised Controlled Trial, number ChiCTR-DT-00000409. The analysis showed statistical difference in the accuracy of T staging between arm A and B (94.6% vs. 77.8%, P = 0.003) and arm A and C (94.6% vs. 80.6%, P = 0.010). Statistical difference was also observed between the accuracies of preoperative N staging between arm A and C (85.1% vs. 69.4%, P = 0.023) and arm A and B (85.1% vs. 84.7%, P = 0.029). Surgical decision making in arm A was more accurate than that in arm C (95.9% vs. 80.6%, P = 0.001). Pathological T stage (P < 0.001), N stage (P < 0.001), tumor node metastasis stage (P < 0.001), serum level of SAA (P = 0.002), and tumor height (P = 0.030) were significantly associated with final surgical procedures. MPE is an effective strategy in preoperative staging and more accurate than other available strategies in surgical decision making for rectal cancer.

21 October 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
XCXi Chen
Xi Chen
XXXinyu Xie
Xinyu Xie
XWXiaodong Wang
Xiaodong Wang
MWMingtian Wei
Mingtian Wei
ZLZhigui Li
Zhigui Li
LLLi Li
Li Li
(1) Background: Practice guidelines recommend neoadjuvant treatment for clinical T4 rectal cancer. The primary objective of this retrospective study was to assess whether compliance with guidelines correlates with patient outcomes. Secondarily, we evaluated predictors of adherence to guidelines and mortality. (2) Methods: A total of 397 qualified rectal cancer (RC) patients from 2017 to 2020 at West China Hospital of Sichuan University were included. Patients were divided into two groups depending on adherence to neoadjuvant treatment guidelines. The main endpoints were overall survival (OS) and disease special survival (DSS). We analyzed factors associated with guideline adherence and mortality. (3) Results: Compliance with guidelines was only 39.55%. Patients’ neoadjuvant therapy treated not according to the guidelines for clinical T4 RC was not associated with an overall survival (95.7% vs. 88.9%) and disease special survival (96.3% vs. 91.1%) benefit. Patients were more likely to get recommended therapy with positive patient compliance. Staging Ⅲ, medium/high differentiation and objective compliance were associated with increased risk of mortality. (4) Conclusions: Guideline adherence for clinical T4 RC in our system is low. Compliance with the relevant guidelines for neoadjuvant therapy seems not to lead to better overall survival for patients with clinical T4 RC.

12 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
XWXiaodong Wang
Xiaodong Wang
ZTZeng Teng
Zeng Teng
BZBoyan Zhou
Boyan Zhou
YLYang Lie
Yang Lie
LLLi Li
Li Li
Background/Objectives: As survival after colorectal cancer improves, more patients live with the consequences of the disease and its treatment, yet years lived with disability (YLDs) are rarely analysed as a primary outcome. We examined whether the colorectal cancer burden is shifting from premature death towards life with disability. Methods: Using Global Burden of Disease (GBD) 2023 estimates for the world, the five Socio-demographic Index (SDI) quintiles and China, we analysed YLDs, years of life lost (YLLs) and the age-standardised YLD share of disability-adjusted life-years (morbidity share) from 1990 to 2023 with joinpoint regression, and decomposed the change in YLD counts into population growth, population ageing and change in age-specific rates. Results: Global YLDs rose from 434,965 to 1,125,290 (+158.7%); the age-standardised YLD rate rose by 10.5% while the YLL rate fell by 22.1%. The morbidity share increased from 3.06% to 4.28% globally and from 2.06% to 4.69% in China, which overtook the global level in 2018. A rising YLD rate with a falling YLL rate was found globally, in the two higher SDI quintiles and in China; in the three lower quintiles both rates rose. The global increase in the YLD rate was confined to men (+19.8%; women −1.5%). Population growth and ageing accounted for 43.4% and 45.9% of the global increase in YLD counts. Conclusions: In higher-SDI settings and in China, the colorectal cancer burden is shifting from premature death towards life with disability, whereas in lower-SDI settings both components are still rising. Survivorship services should be planned for a disability burden concentrated among men and older adults.